抗CGRP抗体による治療反応の予測による慢性化片頭痛の予防に関する研究 (PREDI-CGRP)
片頭痛における抗CGRPモノクローナル抗体による治療に対する反応の予測研究
Being able to predict each patients response to a specific treatment can mean a significant improvement in socioeconomic costs, but above all in their quality of life. With the present study, the investigators aim to analyze in a combined way different clinical, biological and neuroimaging variables, which allow the clinical staff to anticipate the response to treatment with anti-CGRP monoclonal antibodies in patients with migraine.
調査の概要
詳細な説明
The study consists of an initial visit coinciding with the start of treatment, a subsequent visit after 6 months of treatment and finally another after 12 months, coinciding with the end of treatment. In case of worsening after suspension, a clinical visit will be carried out at the time of worsening to evaluate the reintroduction of the drug and in case of reintroduction, a visit will be carried out after 3 months. If patients do not worsen, a visit will be made 6 months after completing treatment.
At each visit, demographic and clinical variables will be collected. In addition, 3 blood tests will be performed corresponding to the beginning of treatment, after 6 months and a month and a half from the last infiltration. Likewise, a brain MRI will be obtained prior to the start of treatment. These blood samples and neuroimaging data will be processed for subsequent analysis.
研究の種類
入学 (実際)
連絡先と場所
研究場所
-
-
Aragon
-
Zaragoza、Aragon、スペイン、50009
- Hospital Clínico Universitario Lozano Blesa
-
-
Basque Country
-
Donostia / San Sebastian、Basque Country、スペイン、20014
- Hospital Universitario Donostia
-
-
Cantabria
-
Santander、Cantabria、スペイン、39008
- Hospital Universitario Marqués de Valdecilla
-
-
Castille and León
-
Valladolid、Castille and León、スペイン、47010
- Hospital Clínico Universitario de Valladolid
-
-
Catalonia
-
Barcelona、Catalonia、スペイン、08035
- Hospital Universitari Vall d'Hebron Research Institute
-
-
Madrid
-
Madrid、Madrid、スペイン、28006
- Hospital Universitario de La Princesa
-
-
Valencia
-
Valencia、Valencia、スペイン、46026
- Hospital Universitario Politécnico La Fe
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
Patients aged between 18 and 65 years with a diagnosis of episodic or chronic migraine who, at the discretion of their neurologist and according to clinical practice guidelines and standard of care, receive treatment with monoclonal antibodies against CGRP (Galcanezumab, Fremanezumab, Eptinezumab) or its receptor (Erenumab) be included. These patients will come from 7 Headache Units in Spain belonging to the following hospitals:
- La Princesa University Hospital
- Vall d'Hebron University Hospital
- Marqués de Valdecilla University Hospital
- Valladolid University Clinical Hospital
- Donostia University Hospital
- Lozano Blesa University Clinical Hospital
- La Fe Polytechnic University Hospital
説明
Inclusion Criteria:
- Patients aged between 18 and 65 years.
- Caucasian ethnicity.
- Patients diagnosed with migraine with and without high-frequency episodic aura (more than 8 days of migraine per month) or chronic by a neurologist expert in headaches and according to the criteria proposed in the International Classification of Headache Diseases, 3rd edition (ICHD- 3).
- Have at least one year of history of migraine.
- Patients must maintain stable preventive treatment in the previous month and not have received botulinum toxin in the month prior to starting the monoclonal antibody.
- Patients able to describe their clinical situation and the characteristics of their headache.
- Grant your informed consent.
Exclusion Criteria:
- Patients who present with another type of non-migraine headache, with the exception of headache due to excessive use of analgesic medication.
- Neurological focus in the examination.
- Pregnancy or breastfeeding period.
- Patients with cognitive deficiency or pathology that may prevent or hinder the correct completion of the study.
- Patients who require changes in preventive treatment during the first 6 months after starting treatment with monoclonal antibodies.
- Patients who present any significant adverse effect that requires withdrawal or change of anti-CGRP drug.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:COHORT
- 時間の展望:PROSPECTIVE
コホートと介入
グループ/コホート |
介入・治療 |
|---|---|
|
Patients with migraine under treatment with monoclonal antibodies against CGRP
Patients with diagnosis of episodic or chronic migraine who, under the criteria of their neurologist and according to the clinical practice guidelines and standard of care, receive treatment with monoclonal antibodies against CGRP (Galcanezumab, Fremanezumab, Eptinezumab) or else its receptor (Erenumab) will be included. |
The patient will keep a record of the presence/absence of headache, average intensity, and need for acute medication. Each patient performs different scales that measure the impact of the migraine on their daily life as well as the disability it may be causing. In turn, each patient performs different scales that measure associated comorbidities such as depression, anxiety or insomnia. Erenumab, Galcenazumeb, Fremanezumab, Eptinezumab |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Biomarkers of positive initial response to monoclonal antibodies
時間枠:From the beginning of treatment, which is the initial visit, to 18 months of follow-up
|
Establish clinical, demographic, transcriptomic, genetic, molecular and/or radiological characteristics that allow predicting a positive initial response to monoclonal antibodies (biomarkers of therapeutic response). |
From the beginning of treatment, which is the initial visit, to 18 months of follow-up
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Sustained response factors
時間枠:From the beginning of treatment, which is the initial visit, to 18 months of follow-up
|
To analyze sustained response factors at the sociodemographic, clinical, transcriptomic, genetic, molecular and/or radiological level after the suspension of anti-CGRP drugs. |
From the beginning of treatment, which is the initial visit, to 18 months of follow-up
|
|
Sustained response after discontinuation of the anti-CGRP antibody
時間枠:From the beginning of treatment, which is the initial visit, to 18 months of follow-up
|
To quantify the proportion of patients who present a sustained response after discontinuation of the anti-CGRP antibody. |
From the beginning of treatment, which is the initial visit, to 18 months of follow-up
|
|
Non-maintained pharmacological response relation with biomarkers
時間枠:From the beginning of treatment, which is the initial visit, to 18 months of follow-up
|
To characterize whether the non-maintained pharmacological response is related to the variables previously characterized as predictors of chronicity. |
From the beginning of treatment, which is the initial visit, to 18 months of follow-up
|
|
Time until relapse after discontinuation of the anti-CGRP antibody
時間枠:From the beginning of treatment, which is the initial visit, to 18 months of follow-up
|
To determine the time until relapse after discontinuation of the anti-CGRP monoclonal antibody in those patients who, having presented a positive initial response, discontinue it. |
From the beginning of treatment, which is the initial visit, to 18 months of follow-up
|
|
Biomarkers of patients with high-frequency episodic migraine and chronic migraine
時間枠:From the beginning of treatment, which is the initial visit, to 18 months of follow-up
|
To validate possible transcriptomic, genetic, molecular and/or radiological characteristics that allow differentiation between patients with high-frequency episodic migraine and chronic migraine in a national multicenter cohort. |
From the beginning of treatment, which is the initial visit, to 18 months of follow-up
|
協力者と研究者
捜査官
- 主任研究者:Ana Beatriz Gago Veiga、Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
その他の研究ID番号
- PI 23- 3054
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Individual participant data (IPD) will not be shared with other researchers. This decision is based on data protection and confidentiality requirements in accordance with applicable European and national regulations (including GDPR). Given that this is a multicentre observational study conducted in routine clinical practice, access to IPD is restricted to the study investigators for the purposes of the predefined analyses.
Any potential secondary use of the dataset would only be considered in fully anonymized form and subject to prior ethical approval and compliance with applicable data protection legislation.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。